Neuro-Myelitis Optica Treatment: Various Approaches and Explorations
Neuromyelitis Optica Spectrum Disorder (NMOSD), also known as Devic's disease, affects approximately 4,000 people in the United States and nearly 250,000 people worldwide. This debilitating condition, which attacks the optic nerve and spinal cord, has seen significant advancements in its treatment in recent years.
The Food and Drug Administration (FDA) has approved three medications for the treatment of NMOSD in adults who test positive for anti-aquaporin-4 (AQP4): eculizumab, inebilizumab, and satralizumab-mwge. These FDA-approved disease-modifying therapies have demonstrated high effectiveness in reducing relapse frequency. Traditional immunosuppressive medications like rituximab, mycophenolate mofetil, methotrexate, and azathioprine are also commonly used to prevent relapses.
Current NMOSD treatment combines these FDA-approved targeted therapies and traditional immunosuppressants, with plasma exchange (PLEX) as an adjunct for acute attacks. PLEX, a therapy used when corticosteroids are ineffective, helps lower the levels of NMO-IgG in the blood, improving the visual prognosis.
However, it's important to note that there is no cure for NMOSD. PLEX involves multiple sessions, each lasting several hours, and the number of sessions required depends on the severity of the NMOSD attack. Immunotherapies, such as azathioprine, mycophenolate mofetil, and rituximab, are also used for the off-label treatment of NMOSD.
In a 2019 study, early diagnosis and treatment helped improve treatment outcomes and recovery in people with more severe initial attacks on their optical nerve or spinal cord. The initial treatment for an acute NMOSD attack often consists of intravenous corticosteroids, specifically methylprednisolone.
Emerging treatments and ongoing research focus on improving efficacy, safety, and dosing convenience. Examples include Ravulizumab (ULTOMIRIS), a long-acting C5 complement inhibitor, offering less frequent dosing compared to eculizumab and showing promising long-term results in relapse prevention. Other investigational therapies target B-cell function with Bruton's tyrosine kinase (BTK) inhibitors (e.g., orelabrutinib, zanubrutinib) and belimumab (targeting B-cell activating factor) are under study.
Ongoing research continues to look for new and improved ways to treat NMOSD. Clinical trials are studies that determine the effectiveness and safety of new medications and therapies, including for NMOSD. People can find ongoing studies at ClinicalTrials.gov by searching for neuromyelitis optica and a specific area of the country.
Before joining a clinical trial, a person should discuss potential benefits, downsides, and eligibility with their doctor. The International Society For Stem Cell Research recommends asking questions about the purpose, safety, eligibility criteria, follow-up care, researchers' expectations, and potential impact on other healthcare options.
Maintaining remission is critical to a person's overall treatment success for NMOSD. Immunotherapies are used to prevent future NMO attacks, and they suppress the immune system and curb the inflammation driving NMO. It's crucial to remember that while these advancements offer hope, there is still much work to be done in the pursuit of a cure for NMOSD.
- Science has seen significant advancements in the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) in recent years, with the FDA approving medications like eculizumab, inebilizumab, and satralizumab-mwge for adults with the condition.
- These FDA-approved therapies, along with traditional immunosuppressants and plasma exchange, are currently used to treat NMOSD, with immunotherapies like azathioprine, mycophenolate mofetil, and rituximab being used both on-label and off-label.
- Emerging treatments for NMOSD, such as Ravulizumab, a long-acting C5 complement inhibitor, are being researched to improve efficacy, safety, and dosing convenience.
- Ongoing research and clinical trials are focusing on finding new and improved ways to treat NMOSD, including investigational therapies that target B-cell function with Bruton's tyrosine kinase (BTK) inhibitors and belimumab, which targets B-cell activating factor.
